EARNINGS News & Analysis

Morningstar Australia's Equity Market Strategist, Lochlan Halloway, discusses his key takeaways and things to focus on from reporting season. 

Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.

Both of these moated companies annouced solid enough results, but our analysts continue to think the shares are too expensive.

The ASX's biggest healthcare name saw its shares fall after reporting first-half results.

There is a veritable alphabet soup of financial ratios that many investors struggle to comprehend and interpret effectively. 

These stocks are still cheap despite impressive earnings. 

We raise our fair value after strong results but shares are pricey.

Solid global sales and margin expansion are highlights from latest quarter.

We believe the company is in a transition year and results will improve.

We look at the biggest market reactions in our coverage and what our analysts think about the companies.